Rx product news featured in the February 2018 issue of Pharmacy Times.
SEMAGLUTIDEMANUFACTURED BY: Novo Nordisk
INDICATION: The FDA has approved semaglutide (Ozempic) injection 0.5 mg or 1 mg, a once-weekly glucagon-like peptide receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
DOSAGE FORM: Injection: 0.5 mg or 1 mg
FOR MORE INFORMATION: novonordisk-us.com
TALTZMANUFACTURED BY: Eli Lilly
INDICATION: The FDA has approved ixekizumab (Taltz) injection 80 mg/mL for the treatment of adults with active psoriatic arthritis. Ixekizumab was previously approved for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
DOSAGE FORM: Subcutaneous injection, 80 mg/mL
FOR MORE INFORMATION: lilly.com
REPATHAMANUFACTURED BY: Amgen
INDICATION: The FDA has OK’d Amgen’s evolocumab (Repatha) as the first proprotein convertase subtilisin/ kexin type 9 inhibitor to prevent heart attacks, strokes, and coronary revascularizations in adults with established heart disease.
DOSAGE FORM: Subcutaneous injection, 420 mg, once a month
FOR MORE INFORMATION: amgen.com
LONHALAMAGNAIR MANUFACTURED BY: PARI Pharma GmbH, Sunovion
INDICATION: The FDA has approved PARI Pharma’s eFlow closed system nebulizer Magnair together with Sunovion’s glycopyrrolate (Lonhala) inhalation solution for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including bronchitis and/ or emphysema. Lonhala Magnair is the first nebulized long-acting muscarinic antagonist treatment option for patients with COPD.
DOSAGE FORM: Inhalation solution, 25 mcg
FOR MORE INFORMATION: paripharma.com, sunovion.com